HomeClinical TopicsFDA approves Promacta for pediatric patients with chronic ITP

FDA approves Promacta for pediatric patients with chronic ITP

On Aug. 24, the U.S. Food and Drug Administration (FDA) approved Promacta (eltrombopag) to treat chronic immune thrombocytopenic purpura (ITP) in pediatric patients (ages one year and older). Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

Couple talking to NP

Getting Covid Vaccine Won’t Hurt Pregnancy Chances; Getting Covid Could

Couples planning a pregnancy might be relieved to know that getting a Covid vaccine does not hurt their odds of conceiving, according to the...